VCYT RSI Chart
Last 7 days
-3.9%
Last 30 days
-10.0%
Last 90 days
-23.8%
Trailing 12 Months
-14.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 311.2M | 328.6M | 343.1M | 361.1M |
2022 | 250.6M | 268.4M | 283.6M | 296.5M |
2021 | 123.1M | 157.5M | 186.7M | 219.5M |
2020 | 122.0M | 112.5M | 112.7M | 117.5M |
2019 | 101.5M | 108.9M | 116.4M | 120.4M |
2018 | 75.6M | 79.9M | 85.9M | 92.0M |
2017 | 68.0M | 71.7M | 70.6M | 72.0M |
2016 | 51.8M | 54.6M | 60.9M | 65.1M |
2015 | 41.9M | 45.2M | 47.7M | 49.5M |
2014 | 25.0M | 28.6M | 32.8M | 38.2M |
2013 | 14.5M | 17.1M | 19.5M | 21.9M |
2012 | 4.9M | 7.1M | 9.4M | 11.6M |
2011 | 0 | 0 | 0 | 2.6M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 01, 2024 | eastham karin | acquired | 131,900 | 13.19 | 10,000 | - |
Apr 01, 2024 | eastham karin | sold | -216,528 | 21.6528 | -10,000 | - |
Mar 15, 2024 | stapley marc | sold (taxes) | -125,988 | 21.1 | -5,971 | chief executive officer |
Mar 15, 2024 | chambers rebecca | acquired | - | - | 4,318 | chief financial officer |
Mar 15, 2024 | stapley marc | acquired | - | - | 11,780 | chief executive officer |
Mar 15, 2024 | chambers rebecca | sold (taxes) | -46,187 | 21.1 | -2,189 | chief financial officer |
Mar 06, 2024 | wygant jonathan | acquired | - | - | 23,942 | vp, chief accounting officer |
Mar 06, 2024 | mcguire annie | acquired | - | - | 49,880 | svp, general counsel |
Mar 06, 2024 | febbo phillip g. | acquired | - | - | 39,904 | chief scientific & med officer |
Mar 06, 2024 | leite john | acquired | - | - | 49,880 | chief commercial officer-clia |
Which funds bought or sold VCYT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 18, 2024 | Park Place Capital Corp | added | 59.65 | 897 | 4,033 | -% |
Apr 18, 2024 | SJS Investment Consulting Inc. | added | 66.67 | 28.00 | 111 | -% |
Apr 18, 2024 | Allspring Global Investments Holdings, LLC | added | 9.1 | -28,485 | 206,642 | -% |
Apr 18, 2024 | ARK Investment Management LLC | reduced | -8.00 | -54,537,600 | 156,068,000 | 1.08% |
Apr 18, 2024 | Diversified Trust Co | added | 54.36 | 99,154 | 506,577 | 0.01% |
Apr 18, 2024 | Koss-Olinger Consulting, LLC | sold off | -100 | -329,000 | - | -% |
Apr 18, 2024 | AEGON ASSET MANAGEMENT UK Plc | added | 15.15 | -714,000 | 8,872,000 | 0.13% |
Apr 16, 2024 | MCF Advisors LLC | added | 98.91 | 1,525 | 4,056 | -% |
Apr 16, 2024 | Arlington Trust Co LLC | sold off | -100 | -1,541 | - | -% |
Apr 16, 2024 | Artemis Investment Management LLP | reduced | -38.69 | -228,322 | 222,627 | -% |
Unveiling Veracyte Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Veracyte Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 38.7B | 6.8B | -8.22 | 5.66 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.2B | 1.8B | -41.3 | 9.94 | ||||
BMRN | 16.7B | 2.4B | 99.75 | 6.91 | ||||
INCY | 11.8B | 3.7B | 19.67 | 3.18 | ||||
MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -10.84 | 14.45 | ||||
BBIO | 4.4B | - | -6.66 | 60.35 | ||||
AXSM | 3.2B | 270.6M | -13.45 | 11.89 | ||||
ACAD | 2.8B | 726.4M | -45.22 | 3.82 | ||||
ARWR | 2.8B | 240.7M | -9.32 | 12.18 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.94 | 4.47 | ||||
NVAX | 558.4M | 983.7M | -1.02 | 0.57 | ||||
CRBP | 409.4M | 881.7K | -9.18 | 466.16 | ||||
INO | 226.2M | 4.9M | -1.67 | 46.49 | ||||
IBIO | 6.0M | 2.1M | -0.22 | 2.14 |
Veracyte Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 9.0% | 98,199,000 | 90,108,000 | 90,322,000 | 82,422,000 | 80,297,000 | 75,592,000 | 72,864,000 | 67,783,000 | 67,336,000 | 60,370,000 | 55,105,000 | 36,703,000 | 34,536,000 | 31,121,000 | 20,704,000 | 31,122,000 | 29,730,000 | 30,973,000 | 30,136,000 | 29,529,000 | 25,750,000 |
Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9,673,000 | 9,114,000 | 8,777,000 | 8,513,000 | 8,704,000 |
Costs and Expenses | 9.7% | 133,706,000 | 121,847,000 | 98,373,000 | 92,920,000 | 85,717,000 | 85,272,000 | 83,597,000 | 83,031,000 | 79,669,000 | 77,051,000 | 62,579,000 | 82,118,000 | 42,608,000 | 35,187,000 | 31,755,000 | 43,322,000 | 37,927,000 | 32,736,000 | 33,236,000 | 31,596,000 | 28,807,000 |
S&GA Expenses | 3.8% | 25,260,000 | 24,344,000 | 25,756,000 | 26,130,000 | 24,127,000 | 25,678,000 | 24,001,000 | 23,754,000 | 22,212,000 | 21,670,000 | 19,662,000 | 16,296,000 | 13,149,000 | 10,955,000 | 10,701,000 | 17,584,000 | 14,183,000 | 13,088,000 | 13,943,000 | 12,477,000 | 10,066,000 |
R&D Expenses | 40.2% | 18,673,000 | 13,322,000 | 12,541,000 | 12,769,000 | 11,287,000 | 10,773,000 | 9,377,000 | 9,166,000 | 10,252,000 | 8,006,000 | 6,249,000 | 5,336,000 | 4,586,000 | 4,042,000 | 4,169,000 | 4,407,000 | 4,443,000 | 3,643,000 | 3,330,000 | 3,435,000 | 3,125,000 |
EBITDA Margin | -Infinity% | -0.14 | - | -0.01 | -0.01 | -0.04 | -0.07 | -0.09 | -0.11 | -0.28 | -0.34 | -0.36 | -0.49 | -0.23 | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | 9,000 | - | - | - | - | -27,000 | 63,000 | - | -76,000 | 55,000 | 65,000 | 55,000 | -264,000 | 58,000 | 235,000 | 303,000 | 536,000 |
Income Taxes | -971.7% | -2,143,500 | -200,000 | 100,000 | - | 395,500 | -152,000 | -100,000 | -3,000 | -760,000 | -1,400,000 | -152,000 | -3,800,000 | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -2.4% | -30,472,000 | -29,772,000 | -8,277,000 | -8,091,000 | -3,441,000 | -8,875,000 | -9,647,000 | -14,464,000 | -11,317,000 | -15,479,000 | -9,190,000 | -45,663,000 | -8,044,000 | -4,124,000 | -11,025,000 | -11,716,000 | - | - | - | - | - |
EBT Margin | -46.9% | -0.21 | -0.14 | -0.09 | -0.10 | -0.12 | -0.16 | -0.19 | -0.20 | -0.37 | -0.42 | -0.43 | -0.56 | - | - | - | - | - | - | - | - | - |
Net Income | 4.5% | -28,293,000 | -29,618,000 | -8,402,000 | -8,091,000 | -3,844,000 | -8,723,000 | -9,532,000 | -14,461,000 | -10,528,000 | -14,129,000 | -9,038,000 | -41,868,000 | -8,044,000 | -4,124,000 | -11,025,000 | -11,716,000 | -7,458,000 | -730,000 | -2,494,000 | -1,917,000 | -3,105,000 |
Net Income Margin | -41.6% | -0.21 | -0.15 | -0.09 | -0.10 | -0.12 | -0.15 | -0.18 | -0.19 | -0.34 | -0.39 | -0.40 | -0.53 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 14.8% | 13,055,000 | 11,369,000 | 13,002,000 | -3,165,000 | 7,872,000 | 5,312,000 | -2,873,000 | -11,325,000 | 7,605,000 | -3,205,000 | 360,000 | -41,757,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -0.9% | 1,115 | 1,125 | 1,161 | 1,157 | 1,156 | 1,126 | 1,144 | 1,174 | 1,188 | 1,186 | 1,027 | 1,025 | 457 | 454 | 257 | 267 | 275 | 260 | 252 | 124 | 121 |
Current Assets | 5.3% | 286 | 271 | 259 | 252 | 249 | 239 | 235 | 238 | 243 | 229 | 371 | 362 | 376 | 370 | 173 | 181 | 188 | 228 | 220 | 91.00 | 97.00 |
Cash Equivalents | 6.9% | 216 | 202 | 191 | 178 | 154 | 171 | 154 | 164 | 173 | 165 | 328 | 325 | 350 | 346 | 148 | 154 | 160 | 196 | 193 | 68.00 | 79.00 |
Inventory | 1.5% | 16.00 | 16.00 | 12.00 | 13.00 | 14.00 | 14.00 | 15.00 | 12.00 | 11.00 | 10.00 | 7.00 | 6.00 | 5.00 | 4.00 | 7.00 | 6.00 | 7.00 | 7.00 | 5.00 | 4.00 | 3.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | 12.00 | 11.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 |
Goodwill | 1.4% | 703 | 693 | 699 | 700 | 696 | 677 | 690 | 704 | 708 | 714 | 472 | 475 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -0.1% | 71.00 | 71.00 | 78.00 | 76.00 | 81.00 | 78.00 | 80.00 | 88.00 | 91.00 | 79.00 | 56.00 | 51.00 | 36.00 | 31.00 | 31.00 | 37.00 | 36.00 | 29.00 | 28.00 | 40.00 | 41.00 |
Current Liabilities | 7.0% | 61.00 | 57.00 | 58.00 | 56.00 | 63.00 | 58.00 | 59.00 | 63.00 | 64.00 | 50.00 | 36.00 | 33.00 | 17.00 | 14.00 | 13.00 | 19.00 | 17.00 | 17.00 | 15.00 | 14.00 | 13.00 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 13.00 | 24.00 |
LT Debt, Current | - | - | - | - | - | - | 1.00 | 1.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - | - | - | - | 1.00 |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 13.00 | 24.00 |
Shareholder's Equity | -0.9% | 1,044 | 1,054 | 1,083 | 1,081 | 1,075 | 1,048 | 1,064 | 1,085 | 1,097 | 1,107 | 971 | 974 | 421 | 423 | 226 | 230 | 239 | 231 | 224 | 84.00 | 80.00 |
Retained Earnings | -6.4% | -468 | -439 | -410 | -401 | -393 | -389 | -381 | -371 | -357 | -346 | -332 | -323 | -281 | -273 | -269 | -258 | -246 | -239 | -238 | -236 | -234 |
Additional Paid-In Capital | 0.5% | 1,536 | 1,528 | 1,521 | 1,510 | 1,500 | 1,492 | 1,483 | 1,477 | 1,469 | 1,462 | 1,304 | 1,298 | 703 | 696 | 496 | 489 | 486 | 470 | 463 | 320 | 314 |
Shares Outstanding | 0.4% | 73.00 | 73.00 | 73.00 | 72.00 | 72.00 | 72.00 | 71.00 | 71.00 | 68.00 | 70.00 | 65.00 | 63.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 1,700 | - | - | - | 1,400 | - | - | - | 2,700 | - | - | - | 1,300 | - | - | - | 1,300 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 9.7% | 15,552 | 14,171 | 16,671 | -2,172 | 9,744 | 7,026 | -363 | -8,872 | 8,446 | -1,393 | 1,887 | -40,561 | 2,261 | 1,752 | -8,423 | -5,301 | 1,790 | -1,556 | -2,455 | -1,011 | -1,226 |
Share Based Compensation | 3.4% | 7,512 | 7,263 | 10,381 | 7,985 | 6,867 | 7,283 | 5,939 | 6,645 | 6,732 | 7,868 | 4,064 | 3,855 | 3,641 | 3,089 | 3,360 | 2,905 | 2,842 | 2,640 | 2,566 | 1,759 | 1,533 |
Cashflow From Investing | 10.9% | -2,497 | -2,802 | -3,669 | 24,080 | -26,434 | 8,807 | -9,307 | -2,453 | 385 | -165,457 | 1,473 | -575,607 | -888 | -1,635 | -649 | -665 | -41,100 | -226 | -658 | -749 | -454 |
Cashflow From Financing | 486.4% | 645 | 110 | 397 | 1,685 | 93.00 | 1,486 | -75.00 | 1,990 | 173 | 3,215 | 1,920 | 591,012 | 2,911 | 197,513 | 3,390 | -219 | 2,965 | 4,797 | 127,919 | -8,394 | 1,829 |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue: | |||
Total revenue | $ 361,051 | $ 296,536 | $ 219,514 |
Operating expenses: | |||
Research and development | 57,305 | 40,603 | 29,843 |
Selling and marketing | 101,490 | 97,560 | 79,840 |
General and administrative | 86,229 | 73,200 | 101,353 |
Impairment of long-lived assets | 68,349 | 3,318 | 0 |
Intangible asset amortization | 20,570 | 21,354 | 15,981 |
Total operating expenses | 446,846 | 337,617 | 301,417 |
Loss from operations | (85,795) | (41,081) | (81,903) |
Other income, net | 9,183 | 4,654 | 254 |
Loss before income tax benefit | (76,612) | (36,427) | (81,649) |
Income tax (benefit) provision | (2,208) | 133 | (6,086) |
Net loss | $ (74,404) | $ (36,560) | $ (75,563) |
Net loss per common share, basic (in USD per share) | $ (1.02) | $ (0.51) | $ (1.11) |
Net loss per common share, diluted (in USD per share) | $ (1.02) | $ (0.51) | $ (1.11) |
Shares use to compute net loss per common share, basic (in shares) | 72,644,487 | 71,549,204 | 67,890,328 |
Shares use to compute net loss per common share, diluted (in shares) | 72,644,487 | 71,549,204 | 67,890,328 |
Testing revenue | |||
Revenue: | |||
Total revenue | $ 326,542 | $ 250,544 | $ 188,182 |
Operating expenses: | |||
Cost of revenue | 88,913 | 75,317 | 58,860 |
Product revenue | |||
Revenue: | |||
Total revenue | 15,588 | 12,632 | 11,464 |
Operating expenses: | |||
Cost of revenue | 8,666 | 7,820 | 5,887 |
Biopharmaceutical and other revenue | |||
Revenue: | |||
Total revenue | 18,921 | 33,360 | 19,868 |
Operating expenses: | |||
Cost of revenue | $ 15,324 | $ 18,445 | $ 9,653 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 216,454,000 | $ 154,247,000 |
Short-term investments | 0 | 24,605,000 |
Accounts receivable | 40,378,000 | 44,021,000 |
Supplies and inventory | 16,128,000 | 14,294,000 |
Prepaid expenses and other current assets | 12,661,000 | 11,469,000 |
Total current assets | 285,621,000 | 248,636,000 |
Property, plant and equipment, net | 20,584,000 | 17,702,000 |
Right-of-use assets, operating leases | 10,277,000 | 13,160,000 |
Intangible assets, net | 88,593,000 | 174,866,000 |
Goodwill | 702,984,000 | 695,891,000 |
Restricted cash | 876,000 | 749,000 |
Other assets | 5,971,000 | 5,418,000 |
Total assets | 1,114,906,000 | 1,156,422,000 |
Current liabilities: | ||
Accounts payable | 12,943,000 | 11,911,000 |
Accrued liabilities | 38,427,000 | 37,774,000 |
Current portion of deferred revenue | 2,008,000 | 2,613,000 |
Current portion of acquisition-related contingent consideration | 2,657,000 | 6,060,000 |
Current portion of operating lease liabilities | 5,105,000 | 4,070,000 |
Current portion of other liabilities | 101,000 | 186,000 |
Total current liabilities | 61,241,000 | 62,614,000 |
Deferred tax liability | 734,000 | 4,531,000 |
Acquisition-related contingent consideration, net of current portion | 518,000 | 2,498,000 |
Operating lease liabilities, net of current portion | 7,525,000 | 10,648,000 |
Other liabilities | 786,000 | 931,000 |
Total liabilities | 70,804,000 | 81,222,000 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022 | 0 | 0 |
Common stock, $0.001 par value; 125,000,000 shares authorized, 73,264,738 and 71,959,454 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 73,000 | 72,000 |
Additional paid-in capital | 1,536,168,000 | 1,500,191,000 |
Accumulated deficit | (468,121,000) | (393,717,000) |
Accumulated other comprehensive loss | (24,018,000) | (31,346,000) |
Total stockholders' equity | 1,044,102,000 | 1,075,200,000 |
Total liabilities and stockholders' equity | $ 1,114,906,000 | $ 1,156,422,000 |
 | Mr. Marc A. Stapley |
---|---|
 | veracyte.com |
 | Biotechnology |
 | 787 |